Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Salix Pharmaceuticals, Ltd has announced that Salix Pharmaceuticals, Inc has filed a lawsuit in the US District Court of New Jersey against Novel Laboratories for infringement of the patent protecting Osmoprep tablets.
Subscribe to our email newsletter
Salix has an exclusive license to the patent protecting Osmoprep from CDC III, for commercialization of Osmoprep in the US.
The lawsuit is in response to an abbreviated new drug application filed by Novel with the FDA regarding Novel’s intent to market a generic version of Osmoprep in the US prior to the May 18, 2013 expiration of US patent.
Salix said that it has full confidence in the intellectual property rights that protect Osmoprep. Moreover, Salix intends to use all reasonable means at its disposal to continue to vigorously defend and enforce the intellectual property rights protecting Osmoprep.